Lv11
50 积分 2025-11-04 加入
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
23天前
已完结
Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime
3个月前
已完结
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
4个月前
已完结
Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study
5个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
5个月前
已完结
Medical treatment for active breast cancer brain metastases
5个月前
已关闭
Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
5个月前
已完结
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
6个月前
已完结
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
6个月前
已完结
皖公网安备34019202002308
